← Back to ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 30/07/2026Mar 2026Filed 30/07/2026Sep 2025Filed 30/10/2025Jun 2025Filed 30/07/2026Mar 2025Filed 30/07/2026Sep 2024Filed 30/10/2025Jun 2024Filed 30/10/2025Mar 2024Filed 30/10/2025
$1,291$1,249$774$594$501$660$494
$164$206$251−$72−$18−$112−$17−$66
$1.21$1.84−$0.55−$0.14−$0.87−$0.13−$0.52
138137131130129127126

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.